Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
AIIMS Bibnagar
Eligibility
Inclusion criteria
Inclusion criteria: Age >18 years Both sex Willing to participate in the study Diagnosed case of rheumatoid arthritis (clinically, radiologically, laboratically) Both seropositive and seronegative RA On treatment with DMARDS (single or combination) Intend to receive vaccine against COVID-19 Post COVID-19 (3month after recovery)
Exclusion criteria
Exclusion criteria: Cancer and other autoimmune/ Immune suppressants disorders Patients on immunosuppressive therapy other than DMARDs Allergy and Contraindication to vaccination Patients with active SARS CoV-2 infection Patients on alternative systems of medicine for RA Patients with known interstitial lung disease Pregnant or breastfeeding woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Immunological response- Number of patients with neutralizing antibodies after 1 month, 3months and 6months post vaccination 2.Number of patients with symptomatic infection by COVID-19 during follow-up period 3.Number of patients with worsening /improvement of clinical symptoms of RA Timepoint: one three and six months | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ Proportion of patients with persistent neutralizing antibodies â?? time frame 6month â?¢ Number of RA patients developing adverse effects due to vaccination Mortality in COVD-19 infected RA patients after vaccination Timepoint: ADRs every 15 days | — |
Countries
India
Contacts
Public ContactMadhavi Eerike
AIIMS Bibinagar
Outcome results
None listed